ArticleJACC. Asia2026
Hemolysis After TAVR Using the Fifth-Generation Balloon-Expandable Valve: Comparison With the Third-Generation Valve.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Modern Valve, An Old Complication: Hemolysis Returns With S3UR.JACC. Asia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemolytic anemia (HA) following transcatheter aortic valve replacement (TAVR) using the fifth-generation SAPIEN 3 Ultra RESILIA (S3UR) valves has been reported nationwide since its approval in Japan.
objectivesThe purpose of this study was to investigate the incidence and predictors of hemolysis in fifth-generation S3UR, in comparison with third-generation SAPIEN 3 (S3).
methodsWe studied 230 consecutive patients who underwent transfemoral TAVR using S3 or S3UR between April 1, 2021, and July 31, 2024; 113 S3 and 117 S3UR. Clinically relevant HA was defined as a decline in hemoglobin of ≥2 g/dL from baseline and a nadir hemoglobin <10.0 g/dL, serum lactate dehydrogenase >500 IU/L, serum haptoglobin <10 mg/dL, reticulocyte count >2%, and no other cause of anemia, identified between postprocedure and 30-day follow-up. Incidence of HA between S3 and S3UR, and factors associated with HA in S3UR were evaluated.
resultsS3UR cases, compared with S3, tended to have a lower degree of paravalvular aortic regurgitation (AR); however, the incidence of HA was significantly higher (10 of 117 [8.5%; 95% CI: 4.4%-16.0%] vs 1 of 113 [0.9%; 95% CI: 0.05%-5.5%]; P = 0.006). In S3UR, severe annular calcification, chronic hemodialysis, use of 20-mm valve, no beta-blocker use, and presence of trace or mild paravalvular AR were associated with HA. However, case-based evaluation suggested that associated factors may be multifactorial.
conclusionsIncidence of HA after TAVR was higher in fifth-generation S3UR than in third-generation S3. Annular calcification, chronic hemodialysis, 20-mm size valve, no beta-blocker use, and presence of paravalvular AR were associated with HA in S3UR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.